Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acomplia moving ahead in Japan despite EU suspension

This article was originally published in Scrip

Executive Summary

The recent temporary suspension for Sanofi-Aventis's obesity drug Acomplia (rimonabant) in the EU has so far not affected development plans in Japan. The product has already completed a Phase IIb trial in this market and a Phase III programme is under way for both weight management and obesity-linked type 2 diabetes, with a submission scheduled for next year. These plans remain unchanged, Sanofi-Aventis's local subsidiary told Scrip. The EU suspension followed a review of the cannabinoid receptor blocker, which raised concerns over psychiatric safety (Scrip Online, October 24th, 2008).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts